|
MechanismCDK7 gene inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of EOC237 in Patients With Advanced Solid Tumor
This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.
评估EOC237治疗晚期实体瘤患者的安全性和耐受性,以及药代动力学的I期临床研究
[Translation] Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of EOC237 in patients with advanced solid tumors
评价EOC237的安全性、耐受性,确定EOC237单药治疗的最大耐受剂量、剂量限制性毒性和II期临床推荐剂量和给药方式。
[Translation] Evaluate the safety and tolerability of EOC237, determine the maximum tolerated dose, dose-limiting toxicity, and recommended dose and administration method for Phase II clinical trials of EOC237 monotherapy.
100 Clinical Results associated with EOC Biopharma (Shanghai) Co., Ltd.
0 Patents (Medical) associated with EOC Biopharma (Shanghai) Co., Ltd.
100 Deals associated with EOC Biopharma (Shanghai) Co., Ltd.
100 Translational Medicine associated with EOC Biopharma (Shanghai) Co., Ltd.